Report
Oliver Metzger

Merck KGaA : Q3 review – turnaround for Process solutions

>Q3 review – beat on EBITDA pre level, guidance confirmed - Merck’s Q3 revenues of € 5,266m (+1.8% y-o-y) were driven by organic growth of 3.8% and were 0%/-1% vs ODDO BHF/consensus. On the bottom line, the company reported EBITDA pre of € 1,618m (+11.9% y-o-y, margin 30.7%), 5% ahead of expectations. EPS pre reached € 2.30, in line with expectations. The 2024 guidance was confirmed with revenues in the range of € 20.7bn to € 22.1bn, trending towards the lower half of...
Underlying
Merck KGaA

Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Oliver Metzger

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch